Today’s B4 Daily comes from B4 Legal Expert Zickie Lim, Partner and Head of Venture Capital at Mills & Reeve, who explains that success is increasingly determined not simply by breakthrough science, but by the quality of a company’s preparation.
The UK’s biotech sector continues to prove its resilience, but the investment landscape has changed. Capital is still flowing, particularly into the Oxford-Cambridge Growth Corridor, yet investors are becoming far more selective about where they place their money. (Mills & Reeve)
Investors are now looking beyond exciting technology. They want to see:
- A clear and credible growth strategy
- Strong corporate governance
- Well-managed intellectual property
- Robust commercial planning
- A management team capable of delivering long-term value (Mills & Reeve)
This shift is particularly relevant to businesses across Oxfordshire. As one half of the world-renowned Oxford-Cambridge Growth Corridor, the region remains one of Europe’s leading centres for life sciences, deep tech and innovation. Continued infrastructure investment and growing international interest mean opportunities remain significant—but only for businesses that are investment ready. (Mills & Reeve)
Zickie also highlights how many biotech companies are broadening their funding strategies, combining traditional venture capital with research partnerships, venture debt and strategic collaborations to preserve equity while continuing to innovate. (businessweekly.co.uk)
The message is clear: in today’s market, preparation is becoming a competitive advantage.
B4 Legal Expert: Zickie Lim, Partner and Head of Venture Capital, Mills & Reeve
#B4Daily #B4Business #LegalExpert #Biotech #LifeSciences #Innovation #Investment #VentureCapital #Oxford #OxfordshireBusiness #Growth #BusinessLeadership